Patients at risk for peritoneal surface malignancy of colorectal cancer origin: The role of second look laparotomy

Journal of Cancer

Volumn 4, Issue 3, 2013, Pages 262-269

  Brücher, Björn L D M ^a   Stojadinovic, Alexander ^b,h,i   Bilchik, Anton J ^c,h   Protic, Mladjan ^d,h   Daumer, Martin ^e,h   Nissan, Aviram ^f,h   Avital, Itzhak ^g,h  

^a Theodor Billroth Academy   (Germany)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NOVI SAD   (Serbia)

^e Sylvia Lawry Centre   (Germany)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g Bon Secours Cancer Institute   (United States)

^h International Consortium of Research Excellence   (Germany)

ⁱ US Military Cancer Institute   (United States)

Author keywords

Carcinomatosis; Clinical trials; Colorectal cancer; CRS; HIPEC; Oxaliplatin and mitomycin; Prospective; Randomized

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOSIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IMMUNO POSITRON EMISSION TOMOGRAPHY; MALIGNANT ASCITES; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PERITONEAL CARCINOMATOSIS; PERITONEAL DISEASE; PERITONEAL SURFACE MALIGNANCY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND LOOK SURGERY; SYSTEMIC THERAPY; TISSUE ADHESION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84882941790     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5831     Document Type: Review

References (57)

1. Jemal A., et al. Cancer statistics, 2008. CA Cancer J Clin, 2008. 58(2): 71-96
2. Itzhak A, Brücher BLDM, Nissan A, Stojadinovic A: Randomized clinical trials for colorectal cancer peritoneal surface malignancy. Surg Clin North Am 2012; 21(4): 665-688.
3. Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Konigsriner A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest. 2012 Mar; 30(3):209-24.
4. Jayne DG, Fook S, Loi C, Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br J Surgery 2002; 89(12):1545-50.
5. Chu DZ, Lang NP, Thompson C, et al. Pertoneal carcinomatosis in non gynecological malignancy: A prospective study of prognostic factors. Cancer 1989; 63: 364-36.
6. Blair SL, Chu DZ, Schwarz RE: Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001; 8: 632-637.
7. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ: Treatment of colorectal peritoneal carcinomatpsis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III Trials N971 and N9841. J Clin Oncol 2012; 30: 263-276.
8. Verwaal V, Ruth S, Bree E, et al: Randomized trial of cytoreduction and hyperthermicintraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737-3743.
9. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005 Jan; 12(1):65-71.
10. Elias D, GIlly F, Boutitie F, et al: Peritoneal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28(1): 63-68.
11. Glehen O, Kwiatkowski F, Sugarbaker P, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi- institutional study. J Clin Oncol 2004; 22(16): 3284-3.
12. Sugarbaker PH: Revised guidelines for second-look surgery in patients with colon and rectal cancer. Clin Transl Oncol. 2010 Sep;12(9):621-8.
13. Sugarbaker P: Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int J Surg Oncol. 2011;2011:915078.
14. Esquivel J,Sugarbaker PH: Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg. 2001 Aug;234(2):198-205.
15. Elias D, Honoré C, Dumont F, et al: Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011 Aug; 254(2):289-93.
16. Maggiori L,Elias D: Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol. 2010 Jul;36(7):599-603.
17. Jacquet P, Sugarbaker PH: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15: 49-58.
18. Wangensteen OH: Cancer of the colon and rectum; with special reference to earlier recognition of alimentary tract malignancy; secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement; subtotal primary excision of the colon; operation in obstruction. Wis Med J 1949; 48: 591-597
19. Wangensteen OH, Lewis FJ, Tongen LA: The second look in cancer surgery: a patient with colic cancer and involve lymph nodes negative on the sixth look. J Lancet 1951; 71(8): 303-307.
20. Griffen WO Jr, Gilbertsen VA,Wangensteen OH: The second look opeation for abdominal malignancies 1948-1963. Natl Cancer Inst Monogr 1964 15: 267-276
21. Bleday R, Steele GJr: Second-look surgery for recurrent colorectal carcinoma: is it worthwhile? Semin Surg Oncol. 1991;7(3):171-6.
22. Bucci L, Benassai G, Santoro GA: Second look in colorectal surgery. Dis Colon Rectum. 1994 Feb;37(2 Suppl):S123-6.
23. Elias D, Goéré D, DiPietrantonio D, Boige V, Malka D, Kohneh-Shahri N, Dromain C, Ducreux M: Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008 Mar;247(3):445-50.
24. Gilbertsen VA, Wangensteen OH: A summary of thirteen years' experience with the second look program. Surg Gynecol Obstet 1962; 114: 438-442.
25. Grotz RL, Pemberton JH: Second look surgery--a shell game? Am J Gastroenterol. 1992 Jun;87(6):804-5.
26. Lefevre JH, Elias DM: Cytoreductive surgery plus intraperitonealchemohyperthermia in patients with colorectal cancer at high risk for local- regional recurrence. Cancer J. 2009;15(3):200-3.
27. Martin EW Jr, James KK, Hurtubise PE, Catalano P, Minton JP: The use of CEA as a nearly indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer. 1977 Feb;39(2):440-6.
28. Martin EWJr, Carey LC: Second-look surgery for colorectal cancer. The second time around. Ann Surg. 1991 Sep;214(3):321-5.
29. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, Fletcher WS, Cruz ABJr, Gatchell FG, Oviedo M, et al: Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985 Mar 15;55(6):1284-90.
30. Osteen RT, Guyton S, Steele G Jr, Wilson RE: Maligant intestinal obstruction. Surgery 1980; 87: 611-615.
31. Portilla AG, Sugarbaker PH, Chang D: Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. WorldJSurg. 1999 Jan;23(1):23-9.
32. Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I: Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials. 2010 May 25;11:62.
33. Rittgers RA, Steele G Jr, Zamcheck N, Loewenstein MS, Sugarbaker PH, Mayer RJ, Lokich JJ, Maltz J, Wilso RE: Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery. J Natl Cancer Inst. 1978 Aug;61(2):315-8.
34. Santoro BT, Griffen WO Jr, Wangensteen C: The second look procedure in the management of ovarian malignancies and pseudomyxomaperitoei. Surgery 1961; 50: 354-358.
35. Spears H, Petrelli NJ, Herrera L, Mitelman A: Treatment of bowel obstruction after operaion for colorectal carcinoma. Am J Surg 1998; 155: 383-386.
36. Walsh HPJ, Schofield PF: Is laparotomy for small bowel obstruction justified in patients with previously treated malignanvy? Br J Surg 1984; 71: 933-935.
37. Zivanovic O, Barakat RR, Sabbatini PJ, Brown CL, Konner JA, Aghajanian CA, Abu-Rustum NR, Levine DA: Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow- up. Cancer. 2008 Jun 15;112(12):2690-7.
38. Glockzin G, Renner P, Popp FC, Dahlke MH, von Breitenbuch P, Schlitt J, Piso P: Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2011; 18(4): 1052-1059.
39. Takahashi S, Kuroiwa G, Hirayama M, Tobioka H: [Advanced poorly differentiated adenocarcinoma of the colon with micropapillarycarcinoma components except specific cytokeratin expressions, report of a case]. NihonShokakibyoGakkaiZasshi. 2011 Dec;108(12):2016-22.
40. Hompes D, Tiek J, Wolthuis A, Fieuws S, Penninckx F, Van Cutsem E, D'Hoore A. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012; [Epub ahead of print].
41. Kojima M, Nakajima K, Ishii G, Saito N, Ochiai A: Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. AmJSurgPathol. 2010 Sep;34(9):1351-60.
42. Takahashi Y, Clearly KR, Mai M, Kitadai Y, Bucana CD, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal type gastric cancer. Clin Cancer Res 1996;2: 1679-1684.
43. Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, et al. Expression of vascular endothelial growth factors in human gastric carcinomas. Pathology International 1998;48: 499-506.
44. Kitadai Y. Angiogenesis and Lymphangiogenesis of gastric cancer. J Oncol 2010;10: 468725.
45. Longo DL: Tumor heterogeneity and personalized medicine. NEJM 2012; 366(10): 956-957.
46. Sangisetty SL, Miner TJ: Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J GastrointestSurg. 2012 Apr 27;4(4):87-95.
47. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single- institution experience. Cancer 2010;116:316-322.
48. Brücher BLDM: Assessment of histopathological response assessment by residual tumor cell quantificatin in esophageal squamous cell carcinoma after neoadjuvant therapy: What for? American Journal of Hematology / Oncology AJSOR 2006; 5(10): 619-624.
49. Brücher BL, Bilchik A, Nissan A, Avital I, Stojadinovic A: Tumor response criteria: are they appropriate? Future Oncol. 2012 Aug;8(8):903-6.
50. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
51. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-170.
52. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinalis F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
53. Bristow RE, Montz FJ: Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005 Nov;99(2):301-8.
54. Knowles SM, Wu AM: Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in oncology. J Clin Oncol 2012; epub.
55. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:4611-4619.
56. Levine EA, Blazer DG 3rd, Kim MK, Shen P, Stewart JH 4th, Guy C, Hsu DS: Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. Jam Coll Surg. 2012 Apr;214(4):599-606.
57. Stojadinovic A, Bilchik A, Smith D, Eberhardt JS, Ward EB, Nissan A, Johnson EK, Protic M, Peoples GE, Avital I, Steele SR: ClinicalDecision- SupportandIndividualizedPredictionofSurvivalinColonCancer: Bayesian Belief Network Model. Ann Surg Oncol. 2012; [Epub ahead of print].